# The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients

Study · id `cardio:ct-nct06503016` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06503016](<https://clinicaltrials.gov/study/NCT06503016>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06503016

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT06503016. Randomized; double masking; primary purpose supportive care. Start 2024-10-08 (actual); primary completion 2026-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose supportive care
- Phase: Phase 3
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT06503016, source copy `cardio:ctgov-nct06503016-2025-08-06`, retrieved 2026-10-26)
- Started: 2024-10-08 (actual) (ClinicalTrials.gov record NCT06503016, source copy `cardio:ctgov-nct06503016-2025-08-06`, retrieved 2026-10-26)
- Primary completion: 2026-04 (anticipated) (ClinicalTrials.gov record NCT06503016, source copy `cardio:ctgov-nct06503016-2025-08-06`, retrieved 2026-10-26)
- Completion: 2026-07 (anticipated) (ClinicalTrials.gov record NCT06503016, source copy `cardio:ctgov-nct06503016-2025-08-06`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT06503016, source copy `cardio:ctgov-nct06503016-2025-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06503016-2025-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients
- Acronym: SPHERE
- Condition: Hypotension
- Condition: Consciousness, Level Altered
- Condition: Airway Disease
- Condition: Respiratory Failure
- Condition: Tachypnea
- Condition: Bradypnea
- Condition: Tachycardia
- Condition: Bradycardia
- Condition: Cardiac Failure
- Condition: Cardiac Arrest
- Intervention (Drug): Phosphocreatine
- Intervention (Drug): Placebo
- Lead sponsor: Università Vita-Salute San Raffaele
- Lead sponsor class: OTHER
- Collaborator: Silvia Ajello
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Bradycardia (`cardio:bradycardia`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)

## Provenance

Content hash: 797b1940e34885518692b3cb5c8a7bd531faa02a6d1ab3a44a247242ddda877d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
